

Ravulizumab Biosimilar - Research Grade

Product Code: ICH5317

More Information

Species Reactivity: Human

Target: Complement C5

Concentration: >1mg/ml

Isotype: Human IgG2(H268Q/F300Y/V309L/A330S/P331S/T339A)-G4 (M428L/N434S)-kappa

Host: CHO Cells

product name H2: Ravulizumab Biosimilar - Research Grade

Antibodies against the same target: [Eculizumab Biosimilar - Research Grade \(ICH4005\)](#), [Vilobelimab Biosimilar - Research Grade \(ICH5285\)](#), [Pozelimab Biosimilar - Research Grade \(ICH5295\)](#), [Crovalimab Biosimilar - Research Grade \(ICH5457\)](#), [Olendalizumab Biosimilar - Research Grade \(ICH5727\)](#), [Omoprubart Biosimilar - Research Grade \(ICH5731\)](#), [Pexelizumab Biosimilar - Research Grade \(ICH5771\)](#), [Tesidolumab Biosimilar - Research Grade \(ICH5918\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P01031

Shipping Conditions: Blue ice

background: This product is a research-grade biosimilar of ravulizumab, supplied as an unconjugated, non-therapeutic analog built around the complement component C5 target for research use only. It is not the clinical drug and is not intended for diagnostic or therapeutic use. Ravulizumab is a long-acting, humanized monoclonal antibody engineered from eculizumab with amino acid substitutions in the Fc and complementarity-determining regions that promote pH-dependent dissociation of C5 within the acidic endosome and

FcRn-mediated antibody recycling, substantially extending serum half-life. The molecule carries an engineered IgG2/IgG4 hybrid framework with the M428L/N434S half-life-extending mutations reflected in the stated isotype. As a research reagent it provides a well-characterized, sequence-defined tool for studying terminal complement inhibition, C5 binding, and pathway blockade in controlled in-vitro systems. It is offered at low endotoxin, in-vivo research-grade standards and in bulk milligram-to-gram quantities suitable for functional assays, benchmarking, and assay development. All content here is guidance for ichorbio to review before publication. Complement component C5 (UniProt P01031) is a central effector of the terminal complement pathway. Following activation of the classical, lectin, or alternative pathways, C5 convertases cleave C5 into C5a and C5b. C5a is a potent anaphylatoxin and chemoattractant that drives inflammation, neutrophil activation, and vascular permeability, while C5b nucleates assembly of the C5b-9 membrane attack complex (MAC), which forms lytic pores in target-cell membranes. Dysregulated terminal complement activity underlies conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Antibodies that bind C5 and block its cleavage prevent generation of both C5a and the MAC, sparing upstream opsonization and immune-complex clearance. Ravulizumab binds C5 with pH-sensitive kinetics, enabling target release and sustained inhibition. C5 is a human protein, making it the relevant species context for this reagent.

Other names: ALXN1210, ALXN-1210, complement 5, C5a anaphylatoxin

Specificity: Detects human Complement C5

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.



Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.